Advances in Nucleic-Based Therapeutics prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Maintaining Heart Function After a Heart Attack
News provided by
Share this article
WASHINGTON, March 4, 2021 /PRNewswire/ An article published in
Experimental Biology and Medicine (Volume 246, Issue 5, March, 2021) (https://journals.sagepub.com/doi/pdf/10.1177/1535370220969844) reports a new therapeutic option for preventing long-term damage to the heart after a heart attack. The study, led by Dr. Y. James Kang, in the Regenerative Medicine Research Center at Sichuan University in Chengdu (China) and the Memphis Institute of Regenerative Medicine at the University of Tennessee Health Science Center in Memphis, TN (USA), reports that inhibition of the copper chaperone COMMD1 blocks myocardial injury and maintains heart function in a mouse model of myocardial ischemia.
Maintaining Heart Function After a Heart Attack prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Share this article
WASHINGTON, Feb. 1, 2021 /PRNewswire/ Recent articles in
Experimental Biology and Medicine highlight new advances in COVID-19 biology and treatment. In an effort to provide the scientific community with important information on COVID-19, at the rapid pace required to protect our global health care workers and bring useful therapies to end the pandemic, manuscripts are being handled at an accelerated rate. To accomplish this our EBM Editor-in-Chief is handling all COVID-19 manuscripts to make sure they receive a thorough but accelerated review. The Publisher of EBM, SAGE, is making sure that accepted COVID-19 manuscripts are processed rapidly, immediately available via On-line First, and are open access. EBM will continue to inform the scientific community and the public of these published articles through press releases.
A New Target for Malaria Vaccines
News provided by
Share this article
WASHINGTON, Jan. 7, 2021 /PRNewswire/ An article published in
Experimental Biology and Medicine (Volume 246, Issue 1, January, 2021, https://journals.sagepub.com/doi/pdf/10.1177/1535370220961764) describes a new target for the development therapies and vaccines for malaria. The study from the West African Centre for Cell Biology of infectious Pathogens at the University of Ghana in Accra (Ghana) reports that peptide antibodies against a new merozoite protein (PF3D7 1459400) block parasite entry into red blood cells.
Malaria is a major global health problem with 2.5 billion people at risk of the disease and death. Global elimination of malaria requires an effective vaccine. Despite the huge public health burden of the disease, limited numbers of vaccine candidates are currently under development, and the most advanced candidates display modest efficacy. The development of an effective malaria vaccine has bee